|
Today's Headlines
FDA approved 27 new drugs last year, down from 39 new medications in 2012, which was a 15-year high, the Associated Press reported. » Full article
|
|
In the last decade, ICU mortality due to severe pneumococcal pneumonia has significantly decreased. Improved survival is associated with earlier antibiotic prescribing and an increased use of combined antibiotic therapy, according to a study reported online in Chest. » Full article
|
|
FDA has approved dapagliflozin tablets (Farxiga, Bristol-Myers Squibb and AstraZeneca) to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. This marks a rebound for the drug, which FDA rejected last year, citing concerns raised by studies linking the drug to bladder cancer and liver toxicity. » Full article
|
|
Baxter International has initiated a voluntary recall in the United States of 2 lots of premixed sterile intravenous parenteral nutrition products: CLINIMIX (Amino Acid in Dextrose) Injection and CLINIMIX E (Amino Acid with Electrolytes in Dextrose with Calcium) Injections to the user level because of complaints of particulate matter found in the products. » Full article
|
|
EDITOR'S PICK
The state of Maine, one of the most rural and conservative states in the Union, took a step recently that none of the more urban and progressive states in the nation has yet attempted.To help its citizens lower their healthcare costs, Maine has passed a law to allow the importation of pharmaceutical products from outside the United States. » Full article
|
|
Continuing Education
This month, Drug Topics offers “Clinical Updates in Diabetes Care,” a knowledge-based activity worth up to 2 credits. The goal of this activity is to assist pharmacists in recognizing and understanding the changes in diabetes care to provide optimal evidence-based care for patients with diabetes. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
Like
Tweet
